For US Healthcare Professionals Only

CLENPIQ is the first and only FDA-approved ready-to-drink low-volume bowel prep1— because completing the prep is an important step towards a successful colonoscopy

See the complete story

CLENPIQ is the first and only FDA-approved ready-to-drink low-volume bowel prep1— because completing the prep is an important step towards a successful colonoscopy

See the complete story

A successful procedure starts with the prep

Split-dose CLENPIQ has established successful cleansing of the entire colon1*

The primary efficacy endpoint was the proportion of patients with successful cleansing of the overall colon, defined as “excellent” or “good” using the Aronchick scale, which is scored before washing of the colon1*

The safety and efficacy of CLENPIQ has been established in clinical trials of another oral formulation of sodium picosulfate, magnesium oxide, and anhydrous citric acid1-3

*Study Design: The safety and efficacy of CLENPIQ has been established based on clinical studies of another oral
formulation of sodium picosulfate, magnesium oxide, and anhydrous citric acid. The efficacy of the split-dose regimen was
evaluated for non-inferiority against a day-before comparator (2L PEG with electrolytes plus 2×5 mg bisacodyl tablets). The
primary efficacy endpoint was the proportion of patients with successful colon cleansing, defined as “excellent” or “good”
using the Aronchick scale. A secondary endpoint was the proportion of patients with successful cleansing of the ascending
colon defined as “excellent,” “good,” or “fair” using the Ottawa scale.

CLENPIQ: Established Safety Profile

†Abdominal bloating, distention, pain/cramping, and watery diarrhea not requiring an intervention were not collected.

RENAL FUNCTION

  • CLENPIQ is contraindicated only in patients with severely reduced renal function (creatinine clearance less than 30mL/minute)2
  • Patients with mild to moderate renal impairment were included in Phase III studies1,3,4
  • Use caution in patients with impaired renal function or taking medications that may affect renal function2

Advise these patients of the importance of adequate hydration before, during, and after the use of CLENPIQ.2,5

Can CLENPIQ help your patients prep for a successful procedure?

CLENPIQ is the first and only FDA-approved, ready-to-drink, low-volume bowel prep2

A successful prep includes hydration before the prep,
during the prep, and after the prep5

CLENPIQ provides easy-to-follow instructions for use

To open the CLENPIQ bottle: Place the bottle on a flat surface. Push down on the cap while twisting to the left (counterclockwise). Twist the cap until you see the white plastic ring under the cap is broken.

Drink, hydrate, repeat

See below for step-by-step instructions.

Encourage patients to hydrate on the day before the
procedure and consume only clear liquids.5

Download easy-to-follow instructions for your patients taking CLENPIQ split-dose
or day-before regimen as appropriate.

Step-By-Step Split-Dose Administration

Dose 1 – On the day before the colonoscopy:

  • Instruct patients to consume only clear liquids (no solid food or dairy) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy.
  • Take the first dose (1 bottle) of CLENPIQ during the evening before the colonoscopy (eg, 5:00 to 9:00 pm).
  • Follow CLENPIQ by drinking five 8-ounce cups (cup provided) of clear liquids (40 ounces total) within 5 hours and before bed.
  • If severe bloating, distention, or abdominal pain occurs following the first dose, delay the second dose until the symptoms resolve.

Dose 2 – Next morning on the day of the colonoscopy (start approximately 5 hours prior to colonoscopy):

  • Continue to consume only clear liquids (no solid food or dairy).
  • Take the second dose (the second bottle) of CLENPIQ.
  • Following the CLENPIQ dose, drink at least three 8-ounce cups (cup provided) of clear liquids (24 ounces) at least 2 hours before the colonoscopy.

Hydration is an important part of the prep

Patients can hydrate with any of the following clear liquids:

  • Water (plain or flavored)
  • Black coffee or tea (no milk, cream, soy,
    or nondairy creamer)
  • Clear broth or bouillon
  • Sports drinks (not red or purple)
  • Clear juices without pulp (such as apple juice or white grape juice)
  • Ginger ale and other sodas (not red or purple)
  • Plain Jell-O (not red or purple)
  • Frozen juice bars (not red or purple)

CLENPIQ is also approved to be used in a day before dosing regimen. Please refer to the Prescribing Information or the Patient Instructions for Use for day-before regimen instructions.

CLENPIQ savings support

Download the CLENPIQ coupon to help patients save

CLENPIQ Coupon

Most patients with commercial insurance pay no more than
$40 OR take $40 off for cash payments*

Download to help patients save

Download the CLENPIQ coupon and your patients may be eligible to pay no more than $40 if they have commercial insurance, or to take $40 off the cash price.

Healthcare providers are eligible to download up to 10 cards at a time.

References

  1. Rex DK, Katz PO, Bertiger G, et al. Split-dose administration of a dual-action, low-volume bowel cleanser for colonoscopy: the SEE CLEAR I study. Gastrointest Endosc. 2013;78(1):132-141.
  2. CLENPIQTM [Prescribing Information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
  3. Katz PO, Rex DK, Epstein M, et al. A dual-action, low-volume bowel cleanser administered the day before colonoscopy: results
    from the SEE CLEAR II study. Am J Gastroenterol. 2013:108(3):401-409.
  4. Bertiger G, Jones E, Dahdal DN, et al. Serum magnesium concentrations in patients receiving sodium picosulfate and
    magnesium citrate bowel preparation: an assessment of renal function and electrocardiographic conduction. Clin Exp
    Gastroenterol    . 2015;8:215-224.
  5. Lichtenstein GR, Cohen LB, Uribarri J. Review article: bowel preparation for colonoscopy—the importance of adequate
    hydration. Aliment Pharmacol Ther. 2007;26(5):633-641.

Indication and Important Safety Information

Indication

CLENPIQ oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults.

Important Safety Information

  • CLENPIQ is contraindicated in the following conditions: patients with severe renal impairment (creatinine clearance less than 30mL/minute), gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of the ingredients in CLENPIQ.
  • Patients should be advised to hydrate adequately (before, during and after use of CLENPIQ), and post-colonoscopy lab tests should be considered if a patient develops significant vomiting or signs of dehydration, including orthostatic hypotension, after taking CLENPIQ. Patients with electrolyte abnormalities should have them corrected before treatment. Use caution when prescribing CLENPIQ for patients that have conditions or are using medications that increase the risk for fluid and electrolyte abnormalities.
  • Use caution in patients who have conditions, or are taking concomitant medications that increase the risk for seizures, such as those taking medications that lower the seizure threshold, patients withdrawing from alcohol or benzodiazepines or patients with known or suspected hyponatremia.
  • Use caution in patients with impaired renal function or taking medications that may affect renal function, as well as patients at increased risk of arrhythmias, including those patients with a history of prolonged QT, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy.
  • Osmotic laxatives may produce colonic mucosal aphthous ulcerations and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of additional stimulant laxatives with CLENPIQ may increase this risk.
  • Use with caution in patients with severe active ulcerative colitis.
  • Use with caution in patients with impaired gag reflex as they may be at risk for regurgitation or aspiration during administration of CLENPIQ.
  • The safety of CLENPIQ has been established from adequate well controlled trials of another oral formulation of sodium picosulfate, magnesium oxide and anhydrous citric acid. The most common adverse reactions in those trials were nausea, headache, and vomiting.
  • CLENPIQ can reduce the absorption of co-administered drugs. Do not take oral medications within one hour of starting CLENPIQ. Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine and penicillamine, at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 800.FDA.1088.
Please see Full Prescribing Information.

Reference
1. CLENPIQTM [Prescribing Information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.

Please see Important Safety Information and Full Prescribing Information

Indication and Important Safety Information

Indication

CLENPIQ oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults.

Important Safety Information

  • CLENPIQ is contraindicated in the following conditions: patients with severe renal impairment (creatinine clearance less than 30mL/minute), gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of the ingredients in CLENPIQ.
  • Patients should be advised to hydrate adequately (before, during and after use of CLENPIQ), and post-colonoscopy lab tests should be considered if a patient develops significant vomiting or signs of dehydration, including orthostatic hypotension, after taking CLENPIQ. Patients with electrolyte abnormalities should have them corrected before treatment. Use caution when prescribing CLENPIQ for patients that have conditions or are using medications that increase the risk for fluid and electrolyte abnormalities.
  • Use caution in patients who have conditions, or are taking concomitant medications that increase the risk for seizures, such as those taking medications that lower the seizure threshold, patients withdrawing from alcohol or benzodiazepines or patients with known or suspected hyponatremia.
  • Use caution in patients with impaired renal function or taking medications that may affect renal function, as well as patients at increased risk of arrhythmias, including those patients with a history of prolonged QT, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy.
  • Osmotic laxatives may produce colonic mucosal aphthous ulcerations and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of additional stimulant laxatives with CLENPIQ may increase this risk.
  • Use with caution in patients with severe active ulcerative colitis.
  • Use with caution in patients with impaired gag reflex as they may be at risk for regurgitation or aspiration during administration of CLENPIQ.
  • The safety of CLENPIQ has been established from adequate well controlled trials of another oral formulation of sodium picosulfate, magnesium oxide and anhydrous citric acid. The most common adverse reactions in those trials were nausea, headache, and vomiting.
  • CLENPIQ can reduce the absorption of co-administered drugs. Do not take oral medications within one hour of starting CLENPIQ. Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine and penicillamine, at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 800.FDA.1088.
Please see Full Prescribing Information.